Compare · AARD vs HRMY
AARD vs HRMY
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and Harmony Biosciences Holdings Inc. (HRMY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and HRMY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- HRMY is the larger of the two at $1.98B, about 59.7x AARD ($33.3M).
- AARD has been more active in the news (9 items in the past 4 weeks vs 5 for HRMY).
- HRMY has more recent analyst coverage (25 ratings vs 17 for AARD).
- Company
- Aardvark Therapeutics Inc.
- Harmony Biosciences Holdings Inc.
- Price
- -
- -
- Market cap
- $33.3M
- $1.98B
- 1M return
- -
- -9.81%
- 1Y return
- -
- -1.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 9
- 5
- Recent ratings
- 17
- 25
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Latest AARD
- SEC Form 10-Q filed by Aardvark Therapeutics Inc.
- Chief Executive Officer Lee Tien-Li was granted 793,951 stock options and returned 793,951 stock options to the company (SEC Form 4)
- Officer Sun Nelson was granted 304,094 stock options and returned 304,094 stock options to the company (SEC Form 4)
- Chief Medical Officer Jaiman Manasi was granted 374,560 stock options and returned 374,560 stock options to the company (SEC Form 4)
- Aardvark Therapeutics downgraded by Raymond James
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
- AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
Latest HRMY
- SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
- Amendment: SEC Form 8-K/A filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Ladenburg Thalmann initiated coverage on Harmony Biosciences with a new price target
- SEC Form 8-K filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
- Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
- CHIEF MEDICAL OFFICER Budur Kumar exercised 38,452 shares at a strike of $30.40 and sold $1,655,416 worth of shares (38,452 units at $43.05) as part of a pre-agreed trading plan (SEC Form 4)